Trauma Under Psychedelics: MDMA Shows Protective Effects During the Peritraumatic Period

Netzer and colleagues frame the study within the well‑established observation that exposure to traumatic events (TEs) can precipitate disorders such as PTSD and depression, and that individuals vary markedly in their acute physiological, cognitive and emotional responses to trauma. Recent work has highlighted the therapeutic promise of psychoactive compounds, particularly MDMA‑assisted psychotherapy for chronic PTSD; however, almost nothing is known about outcomes when severe trauma is experienced while a person is acutely under the influence of psychoactive substances. The investigators capitalised on a tragic natural experiment: the October 7th 2023 terror attack at the Supernova music festival in Israel, where many attendees were under the influence of psychoactive drugs when the mass trauma unfolded. The study set out to examine how substance use at the time of the attack related to subjective experiences during the TE, peritraumatic processing in the following weeks, and early clinical state (mental distress and PTSD symptom severity) assessed four to twelve weeks post‑event. The focus was especially on MDMA because of its known prosocial and fear‑reducing properties and its therapeutic relevance for PTSD.

This was an observational, cross‑sectional analysis nested within an ongoing longitudinal study of survivors from the Supernova attack. The sample comprised 657 adult survivors (406 males; mean age 27.03 ± 6.65) recruited via a survivor support NGO, social media groups and word‑of‑mouth. Data were collected through an anonymous online Qualtrics survey between 26 and 88 days after the event (2 November 2023 to 3 January 2024). Informed consent and institutional ethics approval were obtained. Participants provided demographics and indicated objective exposure metrics (threat to life, personal injuries, harm to loved ones). They reported substances used during the TE (type, quantity, timing relative to the attack, perceived intensity) and rated subjective experiences during the event (feelings of control, isolation, and whether the substance was helpful). Peritraumatic processing measures included perceived social support, social interactions, guilt and sleep quality since the TE; ratings used 0–100 scales with higher scores indicating more extreme manifestations. Current clinical state was assessed with the Kessler Psychological Distress Scale (K6), the PCL‑5 for PTSD symptom severity, and a single 0–100 item on being overwhelmed. Additional questions probed prior trauma, psychiatric/neurological diagnoses, medications, return to work and prior substance experience. Participants were classified into substance groups based on the substance they reported being under at the time of the attack: Hallucinogenic (e.g. psilocybin, LSD), MDMA (MDMA/Ecstasy), Stimulants (cocaine/amphetamines), Light substances (cannabis and/or alcohol), Other (e.g. ketamine, PCP) and No‑Use. The relatively small and heterogeneous Other group (2.6% of sample) was excluded from main analyses; the investigators also stated that analysis of the Hallucinogenic group was beyond the current manuscript's scope. Statistical analyses comprised one‑way ANOVAs to test group differences in substance effects during the TE, peritraumatic processing and current clinical state, with planned one‑tailed t‑test contrasts focused on MDMA versus other groups. Proportion differences were tested with partial chi‑square tests. Multiple comparisons were controlled using False Discovery Rate (FDR). The team also calculated Relative Risk (RR) to compare the probability of attaining predefined favourable outcomes in the MDMA group versus No‑Use, and performed exploratory correlational analyses reporting correlations with p<0.05 and |r|>0.3. The extracted text does not detail certain procedural specifics (for example, thresholds used to define favourable outcomes), nor are full model specifications provided.

Exposure and sample characteristics: All 657 respondents reported direct exposure to life‑threatening events during the attack (100%), 83% witnessed dead or injured individuals, 79% reported loved ones were murdered and 68% reported loved ones were injured; thus all met DSM‑5 Criterion A for PTSD. Substance use during the event: Sixty‑eight percent (n=448) reported consuming at least one substance during the festival. MDMA was the single most commonly reported substance (26.8%), followed by Hallucinogenics (22.9%), light substances (9.0%), stimulants (6.9%) and other substances (2.6%). The No‑Use group comprised 31.8% of participants. Polysubstance use was common, typically involving cannabis or alcohol alongside MDMA or hallucinogens. Most consumption occurred within three hours prior to the attack (74.2%), and participants generally reported being strongly under the influence at the time. Group comparability and demographics: The investigators report a statistically significant difference in sex distribution across substance groups (chi‑square p = 0.03), but no post‑hoc pairwise differences survived correction, and there were no between‑group differences in time from the TE to survey completion (F(3,485)=1.41, p=0.24). Perceived effects during the TE: A statistically significant group difference emerged in ratings of whether the substance assisted during the TE (F(2,277)=4.19, p=0.016, partial η2=0.03). Participants in the MDMA group rated the substance as more helpful (68.12 ± 31.43) than those in the Light group (58.64 ± 32.96); this contrast remained significant after adjustment (p_adj = 0.015). No significant group differences were observed for self‑reported feelings of control or isolation during the TE. Peritraumatic processing and clinical state: Although parts of the results section in the extracted text are truncated, the manuscript reports that MDMA use was associated with improved peritraumatic processing measures compared with other groups. Specifically, survivors who consumed MDMA reported greater perceived social support, more social interactions, and better subjective sleep quality during the one to three months after the event. Clinically, the MDMA group showed lower ratings of being overwhelmed, reduced mental distress and lower PTSD symptom severity in the peritraumatic period compared to participants who did not use MDMA. The authors note that MDMA users showed increased social interactions and support not only versus cannabis/alcohol users but also versus the No‑Use group. Relative risk and correlations: The team defined favourable outcomes by thresholds on the measured scales and found that MDMA users had the highest probability of favourable outcomes; subsequent RR computations comparing MDMA to other groups reportedly favoured MDMA. Exact RR values and thresholds are not provided in the extracted text. Exploratory correlational analyses are reported as statistically significant with |r|>0.3 and p<0.05 prior to multiple‑comparison adjustment, but the extraction does not include the full correlation matrix or specific coefficients. Clinical severity: The mean PCL‑5 score across the sample was 40.88 ± 15.42, which the authors state is above common clinical cutoffs for probable PTSD, indicating substantial symptom burden in the cohort. The extracted results are incomplete in places (figures, some tables and parts of the peritraumatic processing statistics are not fully present), so precise numerical comparisons for several outcomes cannot be reported from the provided text.

Netzer and colleagues interpret their findings as initial evidence that MDMA consumed at the time of an extreme traumatic event may be associated with protective effects during the peritraumatic period. Survivors who reported MDMA use described the substance as having assisted them during the TE and, importantly, exhibited better peritraumatic social processing (more social interactions and greater perceived support), superior subjective sleep quality and lower early clinical symptomatology (less overwhelm, lower mental distress and reduced PCL‑5 scores) one to three months afterwards compared with other substance groups and with those who did not use substances. The authors relate these observations to known pharmacological and behavioural effects of MDMA — notably its prosocial and fear‑reducing properties — and to findings from MDMA‑assisted psychotherapy for PTSD, where enhanced social engagement and reduced threat responses are proposed mediators of therapeutic benefit. Improved sleep is also highlighted as a potential mechanistic contributor, given sleep disturbance’s recognised role in consolidating traumatic memories and its causal links to post‑traumatic psychopathology. The investigators are cautious about causal inference, emphasising the limitations inherent to natural experiments: absence of randomisation and control over confounders, survivor bias (deaths and missing data from non‑survivors), and potential selection bias if those with severe symptoms were less likely to participate. They also note that the present data pertain only to the peritraumatic period, and that PTSD symptom trajectories may evolve over time; the results therefore do not represent the final clinical outcome. The authors acknowledge that some analytic details and full numerical results (for example RR values and some peritraumatic statistics) are not fully presented in the extracted text. Finally, they frame this report as a first set of findings from an ongoing longitudinal effort designed to elucidate cognitive, physiological and neural mechanisms that might underlie the putative protective effects of MDMA, and suggest these observations warrant further investigation rather than definitive clinical conclusions.